Frontiers in Microbiology (Aug 2022)
Advances in the pharmacological treatment of hepatic alveolar echinococcosis: From laboratory to clinic
- Xiaolei Xu,
- Xiaolei Xu,
- Xiaolei Xu,
- Xiaolei Xu,
- Xinye Qian,
- Xinye Qian,
- Cancan Gao,
- Yuan Pang,
- Yuan Pang,
- Hu Zhou,
- Hu Zhou,
- Hu Zhou,
- Lizhen Zhu,
- Lizhen Zhu,
- Zhan Wang,
- Zhan Wang,
- Zhan Wang,
- Mingquan Pang,
- Mingquan Pang,
- Defang Wu,
- Defang Wu,
- Wenhao Yu,
- Wenhao Yu,
- Fanyu Kong,
- Fanyu Kong,
- Dalin Shi,
- Dalin Shi,
- Yuting Guo,
- Yuting Guo,
- Yuting Guo,
- Xiaoxia Su,
- Xiaoxia Su,
- Wang Hu,
- Wang Hu,
- Jun Yan,
- Xiaobin Feng,
- Haining Fan,
- Haining Fan
Affiliations
- Xiaolei Xu
- Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hospital of Qinghai University, Xining, Qinghai, China
- Xiaolei Xu
- School of Clinical Medicine, Tsinghua University, Beijing, China
- Xiaolei Xu
- Qinghai Research Key Laboratory for Echinococcosis, Qinghai, China
- Xiaolei Xu
- Center of Hepatobiliary Pancreatic Disease, Beijing Tsinghua Changgung Hospital, Beijing, China
- Xinye Qian
- School of Clinical Medicine, Tsinghua University, Beijing, China
- Xinye Qian
- Center of Hepatobiliary Pancreatic Disease, Beijing Tsinghua Changgung Hospital, Beijing, China
- Cancan Gao
- Department of General Medicine of Air Force Medical Center, Beijing, China
- Yuan Pang
- Department of Mechanical Engineering, Tsinghua University, Beijing, China
- Yuan Pang
- Biomanufacturing and Rapid Forming Technology Key Laboratory of Beijing, Beijing, China
- Hu Zhou
- Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hospital of Qinghai University, Xining, Qinghai, China
- Hu Zhou
- School of Clinical Medicine, Tsinghua University, Beijing, China
- Hu Zhou
- Qinghai Research Key Laboratory for Echinococcosis, Qinghai, China
- Lizhen Zhu
- Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hospital of Qinghai University, Xining, Qinghai, China
- Lizhen Zhu
- Qinghai Research Key Laboratory for Echinococcosis, Qinghai, China
- Zhan Wang
- Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hospital of Qinghai University, Xining, Qinghai, China
- Zhan Wang
- School of Clinical Medicine, Tsinghua University, Beijing, China
- Zhan Wang
- Qinghai Research Key Laboratory for Echinococcosis, Qinghai, China
- Mingquan Pang
- Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hospital of Qinghai University, Xining, Qinghai, China
- Mingquan Pang
- Qinghai Research Key Laboratory for Echinococcosis, Qinghai, China
- Defang Wu
- Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hospital of Qinghai University, Xining, Qinghai, China
- Defang Wu
- Qinghai Research Key Laboratory for Echinococcosis, Qinghai, China
- Wenhao Yu
- Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hospital of Qinghai University, Xining, Qinghai, China
- Wenhao Yu
- Qinghai Research Key Laboratory for Echinococcosis, Qinghai, China
- Fanyu Kong
- Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hospital of Qinghai University, Xining, Qinghai, China
- Fanyu Kong
- Qinghai Research Key Laboratory for Echinococcosis, Qinghai, China
- Dalin Shi
- Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hospital of Qinghai University, Xining, Qinghai, China
- Dalin Shi
- Qinghai Research Key Laboratory for Echinococcosis, Qinghai, China
- Yuting Guo
- School of Clinical Medicine, Tsinghua University, Beijing, China
- Yuting Guo
- Department of Mechanical Engineering, Tsinghua University, Beijing, China
- Yuting Guo
- Biomanufacturing and Rapid Forming Technology Key Laboratory of Beijing, Beijing, China
- Xiaoxia Su
- Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hospital of Qinghai University, Xining, Qinghai, China
- Xiaoxia Su
- Qinghai Research Key Laboratory for Echinococcosis, Qinghai, China
- Wang Hu
- School of Clinical Medicine, Tsinghua University, Beijing, China
- Wang Hu
- Center of Hepatobiliary Pancreatic Disease, Beijing Tsinghua Changgung Hospital, Beijing, China
- Jun Yan
- Center of Hepatobiliary Pancreatic Disease, Beijing Tsinghua Changgung Hospital, Beijing, China
- Xiaobin Feng
- Center of Hepatobiliary Pancreatic Disease, Beijing Tsinghua Changgung Hospital, Beijing, China
- Haining Fan
- Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hospital of Qinghai University, Xining, Qinghai, China
- Haining Fan
- Qinghai Research Key Laboratory for Echinococcosis, Qinghai, China
- DOI
- https://doi.org/10.3389/fmicb.2022.953846
- Journal volume & issue
-
Vol. 13
Abstract
Hepatic alveolar echinococcosis (HAE) is a zoonotic parasitic disease caused by the larvae of Echinococcus multilocularis. Because of its characteristics of diffuse infiltration and growth similar to tumors, the disability rate and mortality rate are high among patients. Although surgery (including hepatectomy, liver transplantation, and autologous liver transplantation) is the first choice for the treatment of hepatic alveolar echinococcosis in clinic, drug treatment still plays an important and irreplaceable role in patients with end-stage echinococcosis, including patients with multiple organ metastasis, patients with inferior vena cava invasion, or patients with surgical contraindications, etc. However, Albendazole is the only recommended clinical drug which could exhibit a parasitostatic rather than a parasitocidal effect. Novel drugs are needed but few investment was made in the field because the rarity of the cases. Drug repurposing might be a solution. In this review, FDA-approved drugs that have a potential curative effect on hepatic alveolar echinococcosis in animal models are summarized. Further, nano drug delivery systems boosting the therapeutic effect on hepatic alveolar echinococcosis are also reviewed. Taken together, these might contribute to the development of novel strategy for advanced hepatic alveolar echinococcosis.
Keywords
- hepatic alveolar echinococcosis
- drug repurposing
- antibiotic drug
- protease inhibitor
- immune checkpoint inhibitor
